SUMMARY Burn injuries are among the most devastating of all injuries and are the fourth most common type of trauma worldwide. In the United States, there are 1.1 million burn injuries which require medical attention each year. These injuries often result in significant scarring having a negative impact on the… Read More
SUMMARY Small molecule drugs developed to induce trained immunity in macrophage cells resulting in a heightened pro-inflammatory response without triggering a primary immune response The Unmet Need: Trained immunity induction that does not rely on pathogen-derived agents or endogenous molecules and without… Read More
SUMMARY Nutraceutical approach using specific fatty acids naturally found in human breast milk incorporated into infant formula enhancing immune defense in both neonates and adults The Unmet Need: Solutions for effectively bridging maternal and infant health and immune development through diet The field… Read More
SUMMARY Synthetic biology toolsets to genetically manipulate the microbiota, specifically non-model resident gut microbes, to alter gene expression and cellular function to produce therapeutic compounds. Unmet Need: Genetic engineering tools for gut microbes and the development of novel microbiome-based therapeutic and diagnostic systems… Read More
SUMMARY A major attention of vaccine adjuvant development has been focused on development of robust antibody-mediated protection against pathogens. However, such adjuvants have failed to elicit a robust T-cell mediated protection and are thus found to be less efficacious against diseases like malaria, tuberculosis, Ebola and Zika or in immunotherapy. Read More
SUMMARY Inventors devised a nanomedicine termed “Nanotraps” that can completely capture and eliminate SARS-CoV-2 by triggering macrophages to engulf and clear the virus without becoming infected. Ex vivo lung perfusion system. Zero toxicity was found in mice as evidenced by histological analysis of heart, liver, spleen, lung, and kidney, as… Read More
SUMMARY Toll-like receptor (TLR) agonists are considered promising alternatives for the estimated 50 – 75% of all cancer patients who are non-responsive to checkpoint inhibitors, and immune activation is enhanced upon stimulation of two distinct TLRs. However, the use of multiple TLR agonists as an effective therapeutic strategy is presently… Read More